Tuesday, 10 March 2026
PERSPECTA
News from every angle
All
World
Politics
Business
Technology
Finance
Science
Health
Sport
Culture
Opinion
Environment
← Back to headlines
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
9 Mar, 08:46 — 9 Mar, 08:46
Post
Share
Copy link
Embed
Sources
Sort: Relevance
Sort: Latest
Sort: Bias (L→R)
Sort: Bias (R→L)
Sort: Factuality
left
center
right
Showing 1 of 1 sources
Yahoo
Mostly Factual
16h ago
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
Read full article →
Something wrong with this story? Report an issue
Related Stories
Baguio Health Office expands services to include eye test
just now
31% of Nigerian women face physical violence – Report
just now
Yobe residents decry abandoned hospital emergency unit
14m ago
5 tips to relieve heartburn: Lithuanians will like the last one
14m ago
Tuesday, 10 March 2026
Explore
Log in
Sign up
PERSPECTA
News from every angle
